<DOC>
	<DOCNO>NCT01568190</DOCNO>
	<brief_summary>The purpose trial assess tolerability up-dosing phase AVANZ Mite mix .</brief_summary>
	<brief_title>An Open Trial Assess Tolerability AVANZ Mite Mix Immunotherapy</brief_title>
	<detailed_description>The frequency patient adverse reaction primary endpoint .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male female patient 1865 year age . A clinical history HDM induce allergic rhinoconjunctivitis without asthma least one year prior trial entry . Positive SPT Dermatophagoides pteronyssinus ( Der pte ) Dermatophagoides farinae ( Der far ) ( wheal diameter ≥ 3 mm ) . A positive specific IgE Der pte Der far ( ≥Class 2 ; ≥0.70 KU/L ) document last 5 year . FEV1 &lt; 70 % predict value screen adequate pharmacologic treatment . Uncontrolled severe asthma . A clinically relevant history symptomatic perennial allergic rhinitis and/or conjunctivitis cause allergen , subject regularly expose sensitize . History severe asthma exacerbation emergency room visit admission asthma previous 12 month . At screen , current symptom , treatment , upper respiratory tract infection , acute sinusitis , acute otitis medium relevant infection ( serous otitis medium exclusion criterion ) . Treatment parenteral corticosteroid , oral corticosteroid antiIgE previous 3 month study ( except steroid need rescue medication ) . Please , see Table 4 . Currently treat angiotensin convert enzyme ( ACE ) inhibitor , tricyclic antidepressant , βblockers , mono amine oxidase inhibitor ( MAOIs ) drug contain alum ( e.g . antacid ) take daily basis . Previous treatment allergen concomitant IT immunotherapy HDM extract within previous 5 year ( initiation subcutaneous immunotherapy acceptable treatment discontinue reach maintenance dose ; SLIT 3 month last 5 year accept ) . History anaphylactic shock due e.g . food , insect venom , exercise drug . History severe recurrent angioedema . Any contraindication accord Investigator Brochure ( IB ) . Use investigational drug within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>House dust mite sensitisation</keyword>
</DOC>